Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real life review of a single center cohort

Table 2 ADRs of bDMARDs in patients with JIA, JSLE and JDM

	Medications
	ETN	ADA	IFX	TCZ	ABA	RTX	TOTAL
Patients on MED	54	49	36	9	7	10	165
Patients on MED with ADR	10	6	11	2	–	1	30
Patients on MED with ADR(%)	18.5	12.2	30.5	22.2	–	10	18.2
Infections	–	–	1	–	–	1	2
Blood and lymphatic system disorders:
- Thrombocytopenia	–	–	1	–	–	–	1
Nervous system disorders:
- Headache/dizziness/discomfort	–	–	1	–	–	–	1
Eye disorders:
- Uveitis	2	1	–	–	–	–	3
Gastrointestinal disorders:
- Nausea/vomiting	2	3	1	–	–	–	6
- Epigastric pain	–	1	–	–	–	–	1
Hepatobiliary disorders:
-↑ liver enzymes	–	–	–	1	–	–	1
Skin and subcutaneous tissue disorders:
- Atopic dermatitis	1	–	–	–	–	–	1
- Psoriasis	–	1	–	–	–	–	1
- Urticaria	–	–	3	1	–	–	4
Renal and urinary disorders:
- Nephritis	1	–	–	–	–	–	1
- Hematuria	–	1	–	–	–	–	1
General disorders and administration site conditions:
- Anaphylaxis	–	–	2	–	–	–	2
- Local reactions and pain	5	1	2	–	–	–	8
Total number of ADRs	11	8	11	2	–	1	33

ADR - adverse drug reaction, JIA - juvenile idiopathic arthritis, JSLE - juvenile systemic lupus erythematosus, JDM - juvenile dermatomyositis, MED - Medication. Patients on MED- number of patients who used the medication. Patients on MED with ADR- number of patients who used the medication and experienced at least one adverse drug reaction. Patients on MED with ADR(%)- percentage of patients who used the medication and experienced at least one adverse drug reaction = N. P with ADR X 100/N.P on MED. ↑ liver enzymes - elevated liver enzymes. ETN - etanercept (median dose - 1.1 mg/kg/week and median length of treatment - 8.4 months). ADA - adalimumab (median dose - 0.8 mg/kg/dose every 15 days and median length of treatment - 11 months). IFX - infliximab (median dose - 5.4 mg/kg/dose every 8 weeks and median length of treatment - 8.4 months). TCZ - tocilizumab (median dose - 9.7 mg/kg/dose monthly and median length of treatment - 7.5 months). ABA - abatacept (median dose - 10 mg/kg/dose monthly and median length of treatment - 12 months). RTX - rituximab (median dose 1 g/dose twice monthly every 6 months)

ISSN: 2523-3106